

1 Routine Urinary Biochemistry Does Not Accurately Predict Stone Type Nor Recurrence in
2 Kidney Stone Formers: A Multi-Centre, Multi-Model, Externally Validated Machine-Learning
3 Study

4
5 Robert M Geraghty, Ian Wilson, Eric Olinger, Paul Cook, Susan Troup, David Kennedy, Alistair
6 Rogers, Bhaskar K Somani, Nasser A Dhayat, Daniel G Fuster, John A Sayer

7
8 Mr Robert Geraghty - Corresponding Author

9 Academic Clinical Fellow in Urology

10 Department of Urology

11 Freeman Hospital

12 Newcastle-upon-Tyne

13 Rob.geraghty@newcastle.ac.uk

14

15 Dr Eric Olinger

16 Post-Doctoral Researcher

17 Translational and Clinical Institute, Faculty of Medical Sciences, Newcastle University,

18 Central Parkway, Newcastle upon Tyne, England, United Kingdom.

19

20 Dr Ian Wilson

21 Lecturer in Biomedical Statistics

22 Biosciences Institute

23 Newcastle University

24 International Centre for Life

25 Central Parkway

26 Newcastle-upon-Tyne

27

28 Dr Paul Cook

29 Consultant Chemical Pathologist

30 Department of Biochemistry

31 University Hospital Southampton

32 Southampton

33

34 Ms Susan Troup

35 Principal Clinical Biochemist

36 Department of Biochemistry

37 Queen Elizabeth Hospital

38 Gateshead

39

40 Dr David Kennedy

41 Consultant Clinical Biochemist

42 Department of Biochemistry

43 Queen Elizabeth Hospital

44 Gateshead

45

46 Mr Alistair Rogers

47 Consultant Urologist

48 Department of Urology
49 Freeman Hospital
50 Newcastle-upon-Tyne
51
52 Professor Bhaskar Somani
53 Consultant Urologist and Professor of Urology
54 Department of Urology
55 University Hospital Southampton
56 Southampton
57
58 Dr Nasser Dhayat
59 Consultant Nephrologist
60 Department of Nephrology and Hypertension, Inselspital, Bern University Hospital,
61 University of Bern
62 Switzerland
63
64 Professor Daniel Fuster
65 Consultant Nephrologist and Associate Professor of Nephrology
66 Department of Nephrology and Hypertension, Inselspital, Bern University Hospital,
67 Department for Biomedical Research, University of Bern
68 Switzerland
69
70 Professor John Sayer
71 Professor of Nephrology and Honorary Consultant Renal Physician
72 Translational and Clinical Institute, Faculty of Medical Sciences, Newcastle University,
73 Central Parkway, Newcastle upon Tyne, England, United Kingdom.
74 The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Road, Newcastle upon
75 Tyne, England, United Kingdom.
76 National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle
77 upon Tyne, England, United Kingdom.
78
79 **Keywords:** Kidney stones, Machine learning, Prediction, Urinary Biochemistry
80
81 **Word Count:**
82 Abstract: 271/300
83 Main body: 3574/4000
84 References:
85 Figures: 3
86 Tables: 3
87 Appendices: 3

88 Abstract

89 **Objectives:** Urinary biochemistry is used to detect and monitor conditions associated with
90 recurrent kidney stones. There are no predictive machine learning (ML) tools for kidney
91 stone type or recurrence. We therefore aimed to build and validate ML models for these
92 outcomes using age, gender, 24-hour urine biochemistry and stone composition.

93 **Materials and Methods:** Data from 3 cohorts were used, Southampton, UK (n=3013),
94 Newcastle, UK (n=5984) and Bern, Switzerland (n=794). Of these 3130 had available 24-hour
95 urine biochemistry measurements (calcium, oxalate, urate, pH, volume), and 1684 had
96 clinical data on kidney stone recurrence. Two predictive models were constructed (UK and
97 Swiss) using two ML techniques (Partitioning and Random Forests [RF]) and validated
98 internally with a subset of the same dataset (e.g UK model/UK test set), and externally with
99 the other dataset (UK model/Swiss test set).

100 **Results and Limitations:** For kidney stone type, on external validation accuracy of UK RF
101 model=0.79 (95% CI: 0.73-0.84), sensitivity: calcium oxalate=0.99 and calcium
102 phosphate/urate=0.00. Specificity: calcium oxalate=0.00 and calcium
103 phosphate/urate=0.99. For the Swiss RF model accuracy=0.87 (95% CI: 0.83-0.89),
104 sensitivity: calcium oxalate=0.99 and calcium phosphate/urate=0.00. Specificity: calcium
105 oxalate=0.00, calcium phosphate=0.00 and urate=1.00.

106 For stone recurrence, on external validation accuracy of UK RF model=0.22 (95% CI:
107 0.19-0.25), sensitivity=0.93 and specificity=0.09. Swiss RF model accuracy=0.42 (95% CI:
108 0.39-0.47), sensitivity=0.03 and specificity=0.97.

109 **Conclusions:** Neither kidney stone type nor kidney stone recurrence can be accurately
110 predicted using modelling tools built using specific 24-hour urinary biochemistry values
111 alone. Further studies to delineate accurate predictive tools should be undertaken using
112 both known and novel risk factors.

113 Introduction

114 Kidney stones are prevalent¹, costly² and debilitating, with a recurrence rate of
115 around 40-50% at 10 years³. Although there are rare well described forms of kidney stones
116 such as cystinuria leading to cystine stones, the pathophysiology underlying the most
117 common types of kidney stones (calcium stones and urate) have not been satisfactorily
118 described. Given the rising prevalence and cost of surgical treatment, tools are needed to
119 accurately predict kidney stone type and more importantly, risk of recurrence so that
120 preventative measures can be more focused and beneficial.

121 Kidney stone composition may not always be investigated, but remains vital for the
122 identification of rarer stone types that require further management. There has previously
123 been only one machine learning (ML) study that looked at prediction of kidney stone type⁴.
124 Several types of ML models were constructed for kidney stone type prediction, achieving
125 high accuracy (area under the curve (AUC)=0.99), although it was neither internally nor
126 externally validated. They did not use urinary biochemistry, instead utilising demographics
127 and basic medical history. Another study applied logistic regression to 24-hour urinary
128 biochemistries to predict stone type, but this demonstrated poor predictive value⁵.
129 Regression models are not as powerful as more modern ML techniques⁶.

130 The Recurrence of Kidney Stone (ROKS) nomogram was created to predict kidney
131 stone recurrence and is largely based on non-biochemical risk factors and radiologic
132 appearances, rather than biochemistry⁷. It had a moderate predictive value (AUC=0.65) for
133 kidney stone recurrence at 2-years on external validation⁸. Until accuracy improves, this
134 predictive model is not useful for influencing clinical practice.

135 Twenty four hour urine samples are often taken from high-risk stone formers⁹ to
136 identify stone forming risk factors such as hyperoxaluria, hypercalciuria, hyperuricosuria etc.
137 Although the benefit of urinary biochemistry for managing kidney stone patients has not
138 been fully established¹⁰, there is evidence from randomized controlled trials that
139 medications used in specific, limited circumstances reduce the number and increase the
140 time to, recurrence¹¹. A systematic review by Hsi et al. delineates the limitations of 24-hour
141 urine collection, none of the included studies demonstrate any predictive value for
142 recurrence¹⁰.

143 To date there have been no predictive ML models for kidney stone type or
144 recurrence based on 24-hour urinary biochemistry. We therefore aimed to construct
145 predictive ML models for these outcomes using clinical and biochemical data from kidney
146 stone patients to assess the predictive value of 24-hour urinary biochemistry.

148 Methods

149 *Data Collection across all Cohorts*

150 Age, sex, kidney stone recurrence, stone type and 24-hour urinary biochemistry
151 (free-choice diet).

152 Urinary biochemistry obtained: calcium (mmol/24 hour), oxalate (mmol/24 hour),
153 urate (mmol/24 hour), urine volume (L) and pH. Citrate (mmol/24 hour) was obtained from
154 the Newcastle and Bern cohorts.

155 Stone type was ascertained using Fourier Transform IR spectroscopy in all cohorts.
156 Differentiation between calcium oxalate types (monohydrate/dihydrate) was not available
157 in the Southampton/Newcastle cohorts and therefore not included in analysis.

158

159

160

161 Southampton, UK

162 *Study Population*

163 The cohort consisted of patients with kidney stone disease presenting to University
164 Hospital Southampton, UK (tertiary referral hospital) referred for metabolic assessment
165 between 1990-2007. The initial cross-sectional study (n=2801)¹² and subsequent cohort
166 subset² have been described. During this period, stone formers were routinely referred
167 from across Hampshire, Isle of Wight and Dorset. The subset includes 1000 patients with
168 further information ascertained retrospectively using hospital/general practice electronic
169 records.

170 Patients who had no documentation (i.e no evidence of subsequent follow-
171 up/consultation, lived outside/have left Hampshire or no documentation on CHIE) were
172 excluded [see fig. 1].

173

174 *Ethical Approval*

175 Ethical approval for this arm of the study was granted by the NHS Bristol Research
176 Ethics Committee (Rec ref: 18/SW/0185; IRAS ID: 240061).

177

178 Newcastle upon Tyne, UK

179 *Study Population*

180 The cohort consisted of patients with kidney stone disease presenting to hospitals in
181 the north of England between 2013 and 2018 [Appendix 1]. These include: The Newcastle
182 upon Tyne Hospitals NHS Foundation Trust (Newcastle-upon-Tyne), James Cook University
183 Hospital (Middlesbrough), Sunderland Royal Hospital, Durham University Hospital, Queen
184 Elizabeth Hospital (Gateshead), Darlington Memorial Hospital, Cumberland Infirmary
185 (Carlisle) and Northumbria Hospitals Trust (Wansbeck, Hexham, Cramlington).

186 Data ascertained retrospectively using electronic hospital records. Urinary biochemistry
187 and stone type were obtained from the regional renal calculi processing unit (Queen Elizabeth
188 Hospital, Gateshead).

189

190 *Ethical Approval*

191 This arm was registered as an audit (current patients of authors) with Newcastle-
192 upon-Tyne Hospitals NHS Foundation Trust (audit number: 10337).

193

194 Bern, Switzerland

195 *Study Population*

196 Patients enrolled in the Bern Kidney Stone Registry (BKSR) were referred to the
197 Department of Nephrology and Hypertension, Inselspital, Bern University Hospital and
198 included kidney stone formers suffering at least one stone episode. This population has
199 previously been described in the literature¹³. Those <18 years were excluded.

200

201 *Ethical Approval*

202 The BKSR adheres to the Declaration of Helsinki, was approved by the Ethical
203 Committee of the Kanton Bern (#95/06) and all patients provided written informed consent.

204

205 Definitions

206 Stone recurrence was defined as subsequent stone surgery or acute presentation
207 following previous treatment/spontaneous passage. Presence of asymptomatic recurrence
208 on imaging was not available.

209 Low urine volume was defined as <1.5L/24 hour. Acid urine was defined as pH <5.5.

210 Biochemical abnormalities were defined as follows, as per local laboratory values:
211 hypercalciuria in women >6.2 mmol/24 hour and men >7.5 mmol/24 hour; hyperoxaluria in
212 women >0.32 mmol/24 hour, men >0.49 mmol/24 hour; hyperuricosuria as >4.46 mmol/24
213 hour and hypocitraturia as <0.6 mmol/24 hour.

214 Primary kidney stone type was defined as >50% of particular type.


215

216 Statistical Analysis

217 Analysis was performed in R (version no.4.0.2). For robustness, two machine learning
218 models were used: Partitioning (rpart[19]) and Random Forests (randomForest[20] and
219 missForest[21]) for both Stone Type and Recurrence. Missing data was accounted for with
220 values imputed from existing data (missForest). Variables included in both analyses: age,
221 sex, raw 24-hour urinary values (calcium, oxalate, urate, volume), pH and number of
222 biochemical abnormalities. Urinary citrate was excluded due to low numbers with
223 documented citrate. To investigate whether unbalanced data was driving discrimination, up-
224 sampling of training data was used to create balanced training data sets using caret[22],
225 which were run through subsequent analyses.

226 Recurrence rate was excluded in stone type models as this would be unknown at
227 point of presentation. Stone type was included in the recurrence models. Those with
228 unclear stone type were excluded from the Stone Type models. Data was partitioned into
229 training (70% of total) and test (30%) datasets. Diagnostic accuracy statistics are presented
230 in the results section. Sample sizes were not calculated as an effect size was not being
231 calculated. For robustness, two models were used for each measure, and models were
232 constructed from two cohorts. Sensitivity analysis is represented by the second model
233 (random forests), and by the second dataset (Bern).

234



235

236

237

Figure 1. Flow diagram of patient selection/Inclusion. ML=Machine Learning, ST=Stone type, Re=Recurrence.


238 **Results**

239 ***Patient and Biochemistry Demographics***

240 There were 3013 kidney stone patients in the Southampton/Newcastle combined
 241 dataset [see table 1]. There were 2074 men (mean age 49±15 years) and 939 women (mean
 242 age 49±17 years). Stone types were as follows: calcium oxalate (n=1476, 49%), calcium
 243 phosphate (n=119, 4%), urate (n=89, n=3%), cystine (n=5, 0.2%), struvite (magnesium
 244 ammonium phosphate) (n=3, 0.1%) and no data (n=1321, 44%). Those with no data are
 245 likely to have passed their stone/post treatment fragments (e.g. shockwave lithotripsy)
 246 spontaneously. The stone was then not available for analysis. Of these 3013, 890 had
 247 information on whether or not the patient had a kidney stone recurrence. Of these, 374 had
 248 a recurrence (39%). The low numbers of patients with follow-up information are likely due
 249 to the patient not accessing medical services following the initial stone episode, moving
 250 away or dying.

251 There were 794 kidney stone patients in the Bern dataset, with 204 women (mean
 252 age 45±15 years) and 590 men (mean age 48±13 years). Stone types were as follows:
 253 calcium oxalate (n=598, 76%), calcium phosphate (n=81, 10%), urate (n=47, n=6%), cystine
 254 (n=16, 2%), struvite (n=6, 0.8%) and no data (n=40, 5.1%) [see fig 2]. All had follow-up data
 255 available for stone recurrence. There were 676 recurrences (85%).

256 Across all 3 datasets, 3130 patients had full data on urinary biochemistry. There
 257 were 631 (20.1%) patients who had no biochemical diagnoses, 1331 (42.5%) patients with a
 258 single diagnosis and 1668 (37.3%) with a combination of biochemical abnormalities.




259 **Figure 2.** Graphical representation of differences between cohorts and sexes. On top row,
 260 from left to right: bar chart of number of patients in each sex, in each cohort by stone type;
 261 boxplot of age for each sex per stone type; boxplot of 24-hour urinary calcium (mmol/24
 262 hour) for each sex per stone type. Bottom row, from left to right: boxplot of urinary pH for
 263 each sex per stone type; boxplot of 24-hour urinary oxalate (mmol/24 hour) for each sex per
 264 stone type; boxplot of 24 hour urinary uric acid (mmol/24 hour) for each sex per stone type.
 265

266 Of those with full data on urinary biochemistry, 1002 patients had data on kidney
267 stone recurrence. In total 688 (68.7%) had a recurrence. There were 272 (74.7%)
268 recurrences in those with no biochemical diagnosis, 258 (67.0%) with a single biochemical
269 risk factor and 163 (64.4%) in those with a combination [see appendices 2 & 3].

270 The Southampton dataset did not contain 24-hour urinary citrate measurements. In
271 the Newcastle & Bern datasets there were 45 and 121 patients, respectively, with
272 hypocitraturia. Recurrence data was available in 144 patients, with recurrence in 11/23
273 (Newcastle, 47.8%) and 109/121 (Bern, 90.0%), respectively.

274 Discordant primary kidney stone type and 24-hour urine biochemistry was seen in
275 103 patients (5% of known stone type). Cystine stones (n=21) and struvite stones (n=9) were
276 not included in the appendices given their low numbers and alternative aetiologies.

277 Data on subsequent primary stone type was available in the Bern dataset for a
278 subset of those with a stone recurrence (n=188). Change in primary stone type from initial
279 episode was seen in 42 patients (22%): calcium oxalate (n=26, 18%), calcium phosphate
280 (n=10, 37%), urate (n=5, 38%), cystine (n=0, 0%), struvite (n=1, 100%) [Figure 3].



281
282 *Figure 3. Bar chart showing percentage of subsequent stone type for each first stone type,*
283 *data from the Bern Cohort. CaOx=Calcium Oxalate, CaPo=Calcium Phosphate, Ur=Urate,*
284 *Cys=Cystine, Stru=Struvite*

285

		Southampton	Newcastle	Combined Southampton & Newcastle	Bern
	Total, n	2801	212	3013	794
Sex	Female, n	818 (29%)	91 (43%)	939 (31%)	204 (26%)
	Female, Age±SD	49±16	50±19	49±17	45±15
	Male, n	1984 (71%)	121 (57%)	2073 (69%)	590 (74%)
	Male, Age±SD	49±14	48±16	49±15	48±13
Stone Type	Calcium Oxalate, n (%)	1393 (50%)	83 (39%)	1476 (49%)	598 (75.9%)
	Calcium Phosphate, n (%)	59 (2%)	60 (28%)	119 (4.0%)	81 (10.3%)
	Urate, n (%)	55 (2%)	34 (16%)	89 (3.0%)	47 (6.0%)
	Cystine, n (%)	5 (0.2%)	0	5 (0.2%)	16 (2.0%)
	Struvite, n (%)	1 (0.04%)	2 (1%)	3 (0.1%)	6 (0.8%)
	No data, n (%)	1288 (46%)	33 (16%)	1321 (44%)	40 (5.1%)
Recurrence, n/total with data (%)		325/855 (38%)	49/111 (44%)	374/890 (39%)	676/794 (85.1%)

286 *Table 1. Patient and Kidney Stone Demographics. Age in years.*

287 Machine Learning Models:

288 Stone Type

289 The training group had n=3092 patients, n=2360 of which had immediate clearance on
 290 fluoroscopy. On internal validation (test set: n with outcome/total; n=1015/1326), the
 291 diagnostic accuracy statistics were: Random forests (RF) AUC=0.73, accuracy= 0.77 (95%
 292 CI:0.74-0.79), sensitivity=0.27, specificity=0.94; Partitioning AUC=0.63, accuracy=0.71(95%
 293 CI:0.69-0.74), sensitivity=0.22, specificity=0.89; Extreme Gradient Boosting (XGBoost)
 294 AUC=0.75, accuracy=0.77 (95% CI:0.75-0.80), sensitivity=0.27, specificity=0.94; Logistic
 295 Regression (LR) AUC=0.63, accuracy=0.76 (95% CI:0.73-0.78), sensitivity=0.12,
 296 specificity=0.97; Classical Neural Network (NN) AUC=0.74, accuracy=0.75 (95% CI:0.73-0.78),
 297 sensitivity=0.23, specificity=0.94; Bayesian Generalised Linear Model (BGLM)
 298 AUC=0.75, accuracy=0.77 (95% CI:0.75-0.80), sensitivity=0.29, specificity=0.94; Deep Neural
 299 Network (DNN) Single-outcome model AUC=0.59, accuracy=0.77 (95% CI:0.75-0.79),
 300 sensitivity=0.57, specificity=0.79; DNN Multiple-outcome model AUC=0.53,
 301 accuracy=0.77 (95% CI:0.75-0.79), sensitivity=0.60, specificity=0.78 [see figure 2
 302 and supplementary table 2].

303

304 Two models were built to predict kidney stone type, partitioning and Random
305 Forests (RF). Both models used all available 24 hour urinary biochemical data (volume,
306 calcium, oxalate, urate and pH), age and sex. Citrate was excluded as the Southampton data
307 did not have this. Due to missing values (as detailed above), some biochemical values were
308 imputed. Up-sampling of rare stone data, while marginally improving classification into rare
309 stone types, overall gave inferior classification, therefore simple training sets are reported.

310 For the internally validated Southampton/Newcastle models, the partitioning model
311 accuracy was 0.89 (95% CI: 0.85-0.91) and RF model accuracy was 0.90 (95% CI: 0.87-0.92)
312 [see table 3].

313 For the internally validated Bern models, the partitioning model accuracy was 0.75
314 (95% CI: 0.69-0.81) and RF model was 0.81 (95% CI: 0.78-0.84).

315 None of the models were able to predict cystine/struvite stones.

316

317 Each RF model was externally validated using the other dataset. For the
318 Southampton/Newcastle model, validated with Bern data, the accuracy was 0.79 (95% CI:
319 0.73-0.84). The sensitivity for: calcium oxalate=0.99, calcium phosphate/urate=0.00. The
320 specificity for: calcium oxalate=0.00 and calcium phosphate/urate=0.99.

321 For the Bern model, validated with Southampton/Newcastle data, the accuracy was
322 0.87 (95% CI: 0.83-0.89). The sensitivity for: calcium oxalate=0.99, calcium phosphate=0.00
323 and urate=0.04. The specificity for: calcium oxalate=0.02, calcium phosphate=0.99 and
324 urate=1.00.

325 Addition of citrate into the models with the Newcastle and Bern datasets did not
326 demonstrate any difference in accuracy, sensitivity or specificity for stone type. Increasing
327 the predominant stone type threshold for calcium phosphate stones to 90% did not increase
328 accuracy, sensitivity or specificity.

329 Recurrence

330 Two models were used to predict recurrence (Partitioning and RF). Both models used
331 all biochemistry previously described, age and sex. Biochemical value imputation as above.

332 For the internally validated Southampton/Newcastle models, the partitioning model
333 accuracy was 0.52 (95% CI: 0.45-0.60), correctly predicting 25/72 recurrences and 70/109
334 without. The RF model accuracy was 0.55 (95% CI: 0.48-0.63), correctly predicting 25/72
335 recurrences and 75/109 without [see Table 4].

336 For the internally validated Bern models, the partitioning model accuracy was 0.85
337 (95% CI: 0.80-0.89), correctly predicting 201/212 recurrences, and 2/27 without. The RF
338 model accuracy was 0.89 (95% CI: 0.84-0.93), correctly predicting 163/165 recurrences, and
339 1/19 without.

Recurrence	Southampton/Newcastle Model		Bern Model	
	Partitioning	Random Forests	Partitioning	Random Forests
Accuracy (95% CI)	0.52 (0.45-0.60)	0.55 (0.48-0.63)	0.85 (0.80-0.89)	0.89 (0.84-0.93)
Sensitivity	0.64	0.69	0.07	0.05
Specificity	0.35	0.35	0.95	0.99
PPV	0.60	0.61	0.15	0.33
NPV	0.40	0.42	0.89	0.90
Detection Rate	0.39	0.41	0.008	0.005

340 *Table 2. Descriptive statistics for Partitioning and Random Forests models predicting*
341 *recurrence. PPV=positive predictive value, NPV=negative predictive value. Test set=30% of*
342 *same cohort*

343 Each RF model was externally validated as above. The Southampton/Newcastle
344 model, validated with Bern data, accuracy was 0.22 (95% CI: 0.19-0.25), sensitivity=0.93,
345 specificity=0.09, correctly predicting 55/632 recurrences and 108/116 without.

346 The Bern model, validated with Southampton/Newcastle data, accuracy was 0.42
347 (95% CI: 0.39-0.47), sensitivity=0.03, specificity=0.97, correctly predicting 235/242
348 recurrences and 11/332 without.

349 **Addition of citrate into the models with the Newcastle and Bern datasets did not**
350 **demonstrate any difference in accuracy, sensitivity or specificity for stone type. Increasing**
351 **the predominant stone type threshold for calcium phosphate stones to 90% did not increase**
352 **accuracy, sensitivity or specificity.**

353

354 Discussion

355 This study utilised 24-hour urinary biochemistry data from kidney stone patients
356 attending three European tertiary referral centres to make two cohorts
357 (Southampton/Newcastle and Bern), used to construct internally validated machine learning
358 (ML) models for both kidney stone type and kidney stone recurrence. These models were
359 then externally validated on the other cohort. The recurrence models had very poor
360 accuracy, whilst the kidney stone type models demonstrated high overall accuracy. However
361 this is likely due to the high number of calcium oxalate kidney stones in our datasets

362 (reflected in the literature [23]), the diagnostic statistics demonstrate very poor predictive
363 value for other stone types. In essence the models predict every stone as calcium oxalate.

364 The poor predictive value for both outcomes are important negative findings. The
365 composition of most kidney stones is unknown (36% in this study and $\leq 85\%$ in the
366 literature[24]), and 24-hour urine collection is used to identify recurrent/high-risk stone
367 formers who could be started on prophylaxis [11,12].

368 The main strengths of this study are the large cohort sizes, internal & external
369 validation[19,20], multiple ML models (superior to regression analyses[8]) showing similar
370 outcomes and consistent outcomes across both datasets.

371 There are several weaknesses with this study. Few of the Newcastle kidney stone
372 patient cohort had 24-hour urinary biochemical analysis available, and fewer (in both
373 datasets) had data on recurrence. This was addressed with imputation of missing data[21].
374 Unfortunately, 24-hour urinary citrate was not available in the Southampton dataset, which
375 may bias our main results as hypocitraturia is an important risk factor for calcium-containing
376 kidney stones[25]. To investigate this both models were repeated with citrate included for
377 the Bern/Newcastle datasets, this did not demonstrate any improvement in diagnostic
378 statistics. The datasets did not include 24-hour urinary phosphate or sodium, both of which
379 influence the risk of stone formation[26]. Therefore, predictive value may be improved with
380 the addition of these variables. The stone type models could not predict struvite or cystine
381 stones. This is likely due to minimal numbers of these stones, thus underpowering the
382 model, and their alternative pathophysiology[27,28]. Although it is accepted that those with
383 cystinuria, are at high risk of recurrence[28].

384 The datasets differ in terms of stone types proportions, notably uric acid and calcium
385 phosphate stones. For instance, in the Southampton and Bern cohorts uric acid stones
386 represent 3.6% and 6% respectively, whilst in the Newcastle dataset 19% have these (10% of
387 total 5984 patients). Uric acid stones are associated with obesity/metabolic syndrome[29],
388 and this observation may represent rising levels in Newcastle compared to an historic
389 population (Southampton), or a contemporary European population (Bern). This could also
390 represent referral bias, e.g. in the Bern cohort referral rates for urate stones were
391 historically lower than present. As information on BMI or diabetes mellitus was not available
392 this limits the predictive value of the models to predict stone type.

393 Proportions of calcium phosphate stones are also different between datasets (2% in
394 Southampton, whilst 28% in Newcastle). This may be due to selection bias, as large numbers
395 of patients in the Newcastle set did not have urinary biochemistry available. This may also
396 be due to our definition of predominant stone type (i.e $>50\%$). Pure calcium phosphate
397 stones ($>90\%$) are associated with a specific phenotype (alkaline urine and hypocitraturia)
398 [30]. Increasing the cut-off for calcium phosphate stones to $>90\%$ did not demonstrate an
399 increase in predictive power for either stone type or recurrence. This may be due to the low
400 numbers with this stone type (UK: from 4% to 2.8%, Bern: 10.3% to 2.6%). This touches on
401 the wider issue of stone type interpretation. There are no guidelines on how to interpret
402 stone composition, nor are there consistent methods within the literature. It is well known
403 that stones can take many forms/compositions, but translation of these observations has
404 yet to reach everyday practice. Our use of a $>50\%$ cut-off was an attempt to use standard
405 laboratory outputs to improve model accessibility.

406 As well as differences in stone type, recurrence data also differed between datasets,
407 Bern had a far higher rate than the UK cohorts (which are similar to the literature[5]). This is
408 likely due to the selection of patients going to biochemical clinic/tertiary care and will likely

409 skew the results as these patients are not representative of the general stone forming
410 population. This is reflected in the recurrence models, the Bern model predict most as
411 recurrence, whilst the Southampton/Newcastle model predict most as no recurrence.
412 24-hour urinary biochemistry is touted as a good measure to identify urinary risk
413 factors for stone formation[11,12]. In certain circumstances this is true[15], however there
414 are a significant minority of recurrent kidney stone formers who have no biochemical
415 abnormalities (20% in these cohorts and similar to rates seen in other studies[14,31]). This
416 may be due to dietary influence on urinary biochemistry, with a random diet unpredictably
417 influencing the results[32]. Further, a small proportion of patients have discordant urinary
418 biochemistry and stone type (3.3% across these cohorts), which makes prediction of
419 unknown stone type unreliable. In summary, the main challenge to model accuracy was not
420 unbalanced data but a lack of factors that could provide effective discrimination.

421 There is a growing body of evidence that kidney stone disease is the common end
422 point of a heterogenous group of disorders that include environmental[33], dietary[34,35],
423 monogenic[36] and polygenic risk factors[37,38], whether in isolation or combination.
424 Therefore reliance on urinary biochemistry alone as a predictive tool, as this study
425 demonstrates, is inadvisable. This study, along with a recent study demonstrating the futility
426 of serum biochemistry (except calcium)[39], demonstrate that current practices[11,12] to
427 delineate risk of kidney stone recurrence do not work well. At least 15% of kidney stones
428 have a monogenic cause[36], with a significant proportion forming calcium stones[40]. It is
429 evident that a precision medicine approach is needed to differentiate the differing causes of
430 KSD, which may then be treated effectively[41].

431 Future studies are needed to delineate an effective kidney stone screen based on
432 traditional risk factors in combination with kidney stone analysis, 24-hour urinary
433 biochemistry, monogenic screen and polygenic risk scoring.

434 Conclusion

435 Neither kidney stone type nor kidney stone recurrence can be accurately predicted
436 by 24-hour urinary biochemistry. Further studies to delineate an effective stone screen
437 should be undertaken.

438

439 Acknowledgements

440 Robert Geraghty is a National Institute for Health Research Academic Clinical Fellow.
441 Eric Olinger is supported by an Early Postdoc Mobility Stipendium of the Swiss National
442 Science Foundation and Kidney Research UK. John Sayer is funded by Kidney Research UK
443 and the Northern Counties Kidney Research Fund.

444 We would like to acknowledge Dr Valerie Walker for initiating the Southampton
445 stone database.

446

447 References

- 448 [1] Antonelli JA, Maalouf NM, Pearle MS, Lotan Y. Use of the National Health and
449 Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on
450 Cost and Prevalence of Urolithiasis in 2030. *European Urology* 2014;66:724–9.
451 doi:10.1016/j.eururo.2014.06.036.

- 452 [2] Geraghty RM, Cook P, Walker V, Somani BK. Evaluation of the economic burden of
453 kidney stone disease in the UK: a retrospective cohort study with a mean follow-up
454 of 19 years. *BJU Int* 2020;125:586–94. doi:10.1111/bju.14991.
- 455 [3] Lien C-S, Huang C-P, Chung C-J, Lin C-L, Chang C-H. Increased risk of anxiety among
456 patients with urolithiasis: A nationwide population-based cohort study. *Int J Urol*
457 2015;22:937–42. doi:10.1111/iju.12865.
- 458 [4] Canales BK, Sharma N, Yuzhakov SV, Bozorgmehri S, Otto BJ, Bird VG. Long-term
459 Recurrence Rates in Uric Acid Stone Formers With or Without Medical
460 Management. *Urology* 2019;131:46–52. doi:10.1016/j.urology.2019.05.023.
- 461 [5] Ljunghall S, Danielson BG. A Prospective Study of Renal Stone Recurrences. *British*
462 *Journal of Urology* 1984;56:122–4. doi:10.1111/j.1464-410X.1984.tb05346.x.
- 463 [6] Kazemi Y, Mirroshandel SA. A novel method for predicting kidney stone type using
464 ensemble learning. *Artif Intell Med* 2018;84:117–26.
465 doi:10.1016/j.artmed.2017.12.001.
- 466 [7] Moreira DM, Friedlander JI, Hartman C, Elsamra SE, Smith AD, Okeke Z. Using 24-
467 hour urinalysis to predict stone type. *J Urol* 2013;190:2106–11.
468 doi:10.1016/j.juro.2013.05.115.
- 469 [8] Boulesteix AL, Schmid M. Machine learning versus statistical modeling. *Biometrical*
470 *Journal* 2014;56:588–93. doi:10.1002/bimj.201300226.
- 471 [9] Rule AD, Lieske JC, Li X, Melton LJ, Krambeck AE, Bergstralh EJ. The ROKS nomogram
472 for predicting a second symptomatic stone episode. *J Am Soc Nephrol*
473 2014;25:2878–86. doi:10.1681/ASN.2013091011.
- 474 [10] Iremashvili V, Li S, Penniston KL, Best SL, Hedican SP, Nakada SY. External Validation
475 of the Recurrence of Kidney Stone Nomogram in a Surgical Cohort. *J Endourol*
476 2019;33:475–9. doi:10.1089/end.2018.0893.
- 477 [11] Türk C, Petřík A, Sarica K, Seitz C, Skolarikos A, Straub M, et al. EAU Guidelines on
478 Interventional Treatment for Urolithiasis. *European Urology* 2016;69:475–82.
479 doi:10.1016/j.eururo.2015.07.041.
- 480 [12] Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, et al.
481 AUA Guidelines Medical Management of Kidney Stones: AUA Guideline. *Juro*
482 2014;192:316–24. doi:10.1016/j.juro.2014.05.006.
- 483 [13] Eisner BH, Goldfarb DS. A Nomogram for the Prediction of Kidney Stone Recurrence.
484 *Journal of the American Society of Nephrology* 2014:1–3.
485 doi:10.1681/ASN.2013.111180.
- 486 [14] Hsi RS, Sanford T, Goldfarb DS, Stoller ML. The Role of the 24-Hour Urine Collection
487 in the Prevention of Kidney Stone Recurrence. *J Urol* 2017;197:1084–9.
488 doi:10.1016/j.juro.2016.10.052.
- 489 [15] Fink HA, Wilt TJ, Eidman KE, Garimella PS, MacDonald R, Rutks IR, et al. Medical
490 management to prevent recurrent nephrolithiasis in adults: a systematic review for
491 an American College of Physicians Clinical Guideline. *Ann Intern Med* 2013;158:535–
492 43. doi:10.7326/0003-4819-158-7-201304020-00005.
- 493 [16] Walker V, Stansbridge EM, Griffin DG. Demography and biochemistry of 2800
494 patients from a renal stones clinic. *Annals of Clinical Biochemistry* 2013;50:127–39.
495 doi:10.1258/acb.2012.012122.
- 496 [17] Dhayat NA, Lüthi D, Schneider L, Mattmann C, Vogt B, Fuster DG. Distinct
497 phenotype of kidney stone formers with renal phosphate leak. *Nephrol Dial*
498 *Transplant* 2019;34:129–37. doi:10.1093/ndt/gfy170.

- 499 [18] Dhayat NA, Schaller A, Albano G, Poindexter J, Griffith C, Pasch A, et al. The
500 Vacuolar H⁺-ATPase B1 Subunit Polymorphism p.E161K Associates with Impaired
501 Urinary Acidification in Recurrent Stone Formers. *J Am Soc Nephrol* 2016;27:1544–
502 54. doi:10.1681/ASN.2015040367.
- 503 [19] Therneau TM, Atkinson B, Ripley MB. The rpart package 2010.
- 504 [20] Segal MR. Machine Learning Benchmarks and Random Forest Regression 2004.
- 505 [21] Stekhoven DJ. missForest: Nonparametric missing value imputation using random
506 forest. *Astrophysics Source Code Library* n.d.:ascl:1505.011.
- 507 [22] Kuhn M. caret: Classification and Regression Training. *Astrophysics Source Code*
508 *Library* n.d.:ascl:1505.003.
- 509 [23] Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition
510 in men and women. *Urological Research* 2006;34:193–9. doi:10.1007/s00240-006-
511 0042-8.
- 512 [24] Yasui T, Iguchi M, Suzuki S, Kohri K. Prevalence and Epidemiological Characteristics
513 of Urolithiasis in Japan: National Trends Between 1965 and 2005. *Urology*
514 2008;71:209–13. doi:10.1016/j.urology.2007.09.034.
- 515 [25] Eisner BH, Sheth S, Dretler SP, Herrick B, Pais VM. Abnormalities of 24-hour urine
516 composition in first-time and recurrent stone-formers. *Urology* 2012;80:776–9.
517 doi:10.1016/j.urology.2012.06.034.
- 518 [26] Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. *Kidney*
519 *International* 2008;73:489–96. doi:10.1038/sj.ki.5002708.
- 520 [27] Flannigan R, Choy WH, Chew B, Lange D. Renal struvite stones--pathogenesis,
521 microbiology, and management strategies. *Nat Rev Urol* 2014;11:333–41.
522 doi:10.1038/nrurol.2014.99.
- 523 [28] Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al.
524 Pathophysiology and treatment of cystinuria. *Nat Rev Nephrol* 2010;6:424–34.
525 doi:10.1038/nrneph.2010.69.
- 526 [29] Geraghty R, Abdi A, Somani B, Cook P, Roderick P. Does chronic hyperglycaemia
527 increase the risk of kidney stone disease? results from a systematic review and
528 meta-analysis. *BMJ Open* 2020;10:e032094. doi:10.1136/bmjopen-2019-032094.
- 529 [30] Grases F, Costa-Bauzá A, Ramis M, Montesinos V, Conte A. Simple classification of
530 renal calculi closely related to their micromorphology and etiology. *Clin Chim Acta*
531 2002;322:29–36. doi:10.1016/s0009-8981(02)00063-3.
- 532 [31] Gentle DL, Stoller ML, Bruce JE, Leslie SW. Geriatric urolithiasis. *Juro*
533 1997;158:2221–4. doi:10.1016/s0022-5347(01)68203-x.
- 534 [32] Fuster DG, Morard GA, Schneider L, Mattmann C, Lüthi D, Vogt B, et al. Association
535 of urinary sex steroid hormones with urinary calcium, oxalate and citrate excretion
536 in kidney stone formers. *Nephrol Dial Transplant* 2020. doi:10.1093/ndt/gfaa360.
- 537 [33] Yamout H, Goldberg S. Genetic and Environmental Risk Factors for Kidney Stones.
538 *Nutritional and Medical Management of Kidney Stones*, vol. 62, Cham: Humana,
539 Cham; 2019, pp. 43–52. doi:10.1007/978-3-030-15534-6_3.
- 540 [34] Hiatt RA, Ettinger B, Caan B, Quesenberry CP, Duncan D, Citron JT. Randomized
541 controlled trial of a low animal protein, high fiber diet in the prevention of recurrent
542 calcium oxalate kidney stones. *Am J Epidemiol* 1996;144:25–33.
- 543 [35] Fink HA, Akornor JW, Garimella PS, MacDonald R, Cutting A, Rutks IR, et al. Diet,
544 fluid, or supplements for secondary prevention of nephrolithiasis: a systematic

- 545 review and meta-analysis of randomized trials. *European Urology* 2009;56:72–80.
546 doi:10.1016/j.eururo.2009.03.031.
- 547 [36] Halbritter J, Baum M, Hynes AM, Rice SJ, Thwaites DT, Gucev ZS, et al. Fourteen
548 monogenic genes account for 15% of nephrolithiasis/nephrocalcinosis. *J Am Soc*
549 *Nephrol* 2015;26:543–51. doi:10.1681/ASN.2014040388.
- 550 [37] Paranjpe I, Tsao N, Judy R, Paranjpe M, Chaudhary K, Klein D, et al. Derivation and
551 Validation of Genome Wide Polygenic Score for Urinary Tract Stone Diagnosis.
552 *Kidney International* 2020. doi:10.1016/j.kint.2020.04.055.
- 553 [38] Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, et al. Genetic
554 variants of calcium and vitamin D metabolism in kidney stone disease. *Nat Commun*
555 2019;10:5175–10. doi:10.1038/s41467-019-13145-x.
- 556 [39] Eyre KS, Lewis F, Cui H, Grout E, Mihai R, Turney BW, et al. Utility of blood tests in
557 screening for metabolic disorders in kidney stone disease. *BJU Int* 2020.
558 doi:10.1111/bju.15250.
- 559 [40] Hill F, Sayer JA. Precision medicine in renal stone-formers. *Urolithiasis* 2019;47:99–
560 105. doi:10.1007/s00240-018-1091-5.
- 561 [41] Sayer JA, Moochhala SH, Thomas DJ. The Medical Management of Urolithiasis:.
562 *British Journal of Medical and Surgical Urology* 2010;3:87–95.
563 doi:10.1016/j.bjmsu.2010.02.004.

564



565
566

Appendix 1. Study centre locations.

Southampton + Newcastle 24-hour urine finding	Total, n (%) (total n=2521)	Stone Type, n (% of Biochemical Diagnosis)				Recurrence, n/total n (total with data on Recurrence, n=391)
		Calcium Oxalate	Calcium Phosphate	Urate	Unknown	
No abnormality	520 (20.6%)	256 (49.2%)	29 (5.6%)	7 (1.3%)	227 (43.7%)	40/95
Low Urine Volume	344 (13.6%)	166 (48.3%)	11 (3.2%)	3 (0.9%)	164 (47.7%)	21/53
Hypercalciuria	333 (13.2%)	169 (50.8%)	7 (2.1%)	3 (0.9%)	154 (46.2%)	19/39
Hyperoxaluria	172 (6.8%)	84 (48.8%)	4 (2.3%)	1 (0.6%)	81 (47.1%)	6/22
Acid urine	167 (6.6%)	72 (43.1%)	2 (1.2%)	9 (5.4%)	84 (50.3%)	11/32
Hypercalciuria + Hyperoxaluria	134 (5.3%)	66 (49.3%)	5 (3.7%)	0	63 (47.0%)	6/17
Hypercalciuria + Low Urine Volume	128 (5.1%)	70 (54.7%)	2 (1.6%)	1 (0.8%)	55 (43.0%)	9/20
Acid urine + Low Urine Volume	121 (4.8%)	51 (42.1%)	0	11 (9.1%)	59 (48.8%)	6/16
Hypercalciuria + Acid Urine	81 (3.2%)	35 (43.2%)	2 (2.5%)	1 (1.2%)	43 (53.1%)	1/4
Hyperoxaluria + Low Urine Volume	66 (2.6%)	38 (57.6%)	1 (1.5%)	0	27 (40.9%)	2/5
Hyperoxaluria + Acid Urine	47 (1.9%)	25 (53.2%)	1 (2.1%)	1 (2.1%)	20 (42.6%)	0/0
Hyperuricosuria	46 (1.8%)	25 (54.3%)	1 (2.2%)	2 (4.3%)	18 (39.1%)	3/10
Hypercalciuria + Hyperuricosuria	46 (1.8%)	32 (69.6%)	0	0	14 (30.4%)	5/10
Hyperoxaluria + Acid Urine + Low Urine Volume	33 (1.3%)	19 (57.6%)	0	2 (6.1%)	12 (36.4%)	2/7
Hypercalciuria + Hyperoxaluria + Hyperuricosuria	30 (1.2%)	12 (40.0%)	0	1 (3.3%)	17 (56.7%)	4/9
Hypercalciuria + Hyperoxaluria + Acid Urine	29 (1.2%)	15 (51.7%)	0	1 (3.4%)	13 (44.8%)	4/5
Hypercalciuria + Hyperoxaluria + Low Urine Volume	27 (1.1%)	17 (63.0%)	0	0	9 (33.3%)	1/1
Hypercalciuria + Acid Urine + Low Urine Volume	25 (1.0%)	13 (52.0%)	0	0	12 (48.0%)	2/2
Hyperuricosuria + Low Urine Volume	23 (0.9%)	8 (34.8%)	1 (4.3%)	2 (8.7%)	11 (47.8%)	1/2
Hyperuricosuria + Acid Urine	22 (0.9%)	9 (40.9%)	0	3 (13.6%)	10 (45.5%)	4/7
Hyperoxaluria + Hyperuricosuria	21 (0.8%)	11 (52.4%)	0	2 (9.5%)	8 (38.1%)	4/9
Hypercalciuria + Hyperuricosuria + Low Urine Volume	19 (0.8%)	8 (42.1%)	0	0	11 (57.9%)	2/5
Hypercalciuria + Hyperuricosuria	18 (0.7%)	10 (55.6%)	0	1 (5.6%)	7 (38.9%)	2/5

+ Acid Urine						
Hyperuricosuria + Acid Urine + Low Urine Volume	13 (0.4%)	6 (46.2%)	0	4 (30.8%)	3 (23.1%)	2/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine	13 (0.4%)	6 (46.2%)	0	3 (23.1%)	4 (30.8%)	6/8
Hyperoxaluria + Hyperuricosuria + Low Urine Volume	10 (0.3%)	3 (30.0%)	1 (10.0%)	0	6 (60.0%)	1/1
Hyperoxaluria + Hyperuricosuria + Acid Urine	8 (0.3%)	4 (50.0%)	0	0	4 (50.0%)	0/1
Hypercalciuria + Hyperoxaluria + Acid Urine + Low Urine Volume	7 (0.2%)	3 (42.9%)	0	0	4 (57.1%)	0/2
Hypercalciuria + Hyperuricosuria + Acid Urine + Low Urine Volume	7 (0.2%)	3 (42.9%)	0	1 (14.3%)	3 (42.9%)	2/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Low Urine Volume	6 (0.2%)	4 (66.7%)	0	0	2 (33.3%)	0/1
Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	4 (0.1%)	3 (75.0%)	0	0	1 (25.0%)	0/1
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	1 (0.0%)	1 (100.0%)	0	0	0	0/0

567

568 *Appendix 2. Biochemistry diagnoses and recurrences for Newcastle/Southampton dataset.*

569

Bern 24-hour urine finding	Total, n (% (total n=609)	Stone Type, n (% of Biochemical Diagnosis)				Recurrence, n/total n (total with data on Recurrence, n=609)
		Calcium Oxalate	Calcium Phosphate	Urate	Unknown	
No abnormality	111 (18.2%)	85	13	3	3	97/111
Low Urine Volume	80 (13.1%)	65	5	3	4	66/80
Hypercalciuria	53 (8.7%)	43	7	0	2	46/53
Hyperoxaluria	78 (12.8%)	50	13	6	4	71/78
Acid urine	50 (8.2%)	36	2	6	4	41/50
Hypercalciuria + Hyperoxaluria	24 (3.9%)	19	4	0	1	23/24
Hypercalciuria + Low Urine Volume	12 (2.0%)	11	0	0	1	11/12
Acid urine + Low Urine Volume	31 (7.1%)	24	0	5	2	26/31
Hypercalciuria + Acid Urine	5 (0.8%)	5	0	0	0	4/5
Hyperoxaluria + Low Urine Volume	15 (2.5%)	12	0	1	2	11/15
Hyperoxaluria + Acid Urine	32 (5.3%)	26	3	1	2	25/32
Hyperuricosuria	8 (1.3%)	6	1	1	0	8/8
Hypercalciuria + Hyperuricosuria	15 (2.5%)	12	2	0	1	13/15
Hyperoxaluria + Acid Urine + Low Urine Volume	11 (1.8%)	8	0	3	0	11/11
Hypercalciuria + Hyperoxaluria + Hyperuricosuria	15 (2.5%)	11	2	0	2	14/15
Hypercalciuria + Hyperoxaluria + Acid Urine	9 (1.5%)	7	0	1	1	8/9
Hypercalciuria + Hyperoxaluria + Low Urine Volume	2 (0.3%)	2	0	0	0	2/2
Hypercalciuria + Acid Urine + Low Urine Volume	6 (1.0%)	5	0	1	0	5/6
Hyperuricosuria + Low Urine Volume	4 (0.7%)	4	0	0	0	3/4
Hyperuricosuria + Acid Urine	7 (1.1%)	5	2	0	0	5/7
Hyperoxaluria + Hyperuricosuria	11 (1.8%)	8	0	0	1	10/11
Hypercalciuria + Hyperuricosuria + Low Urine Volume	2 (0.3%)	1	1	0	0	2/2
Hypercalciuria + Hyperuricosuria + Acid Urine	7 (1.1%)	5	2	0	0	7/7
Hyperuricosuria + Acid Urine + Low Urine Volume	2 (0.3%)	2	0	0	0	2/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine	5 (0.8%)	4	1	0	0	4/5
Hyperoxaluria + Hyperuricosuria + Low Urine Volume	1 (0.2%)	1 (100%)	0	0	0	1/1

Hyperoxaluria + Hyperuricosuria + Acid Urine	4 (0.7%)	3 (75%)	0	1 (25%)	0	4/4
Hypercalciuria + Hyperoxaluria + Acid Urine + Low Urine Volume	4 (0.7%)	3 (75%)	0	1 (25%)	0	4/4
Hypercalciuria + Hyperuricosuria + Acid Urine + Low Urine Volume	2 (0.3%)	1 (50%)	0	1 (50%)	0	1/2
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Low Urine Volume	1 (0.2%)	1 (100%)	0	0	0	1/1
Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	1 (0.2%)	1 (100%)	0	0	0	1/1
Hypercalciuria + Hyperoxaluria + Hyperuricosuria + Acid Urine + Low Urine Volume	1 (0.2%)	1 (100%)	0	0	0	1/1

570

571 *Appendix 3. Biochemistry diagnoses and recurrences for Bern database.*

572

573